Dr. Reddy's Laboratories Limited (DRREDDY) — Announcement Announcement
📢 Key Event
Dr. Reddy's launches Bosutinib 400mg generically in the US market
💡 Investor Takeaway
This launch expands Dr. Reddy's oncology portfolio and revenue potential in the high-value US market.
Dr. Reddy's Laboratories announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on June 13, 2026, marking its entry into the US oncology market through a partnership with MSN Laboratories. The product targets the $253.8 million US market for Bosulif® and grants 180 days of generic exclusivity.
📄 View Original Announcement (PDF)
About Dr. Reddy's Laboratories Limited (DRREDDY)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Market Cap: ₹1,11,568.6 Cr
P/E: 20.0
ROE: 16.6%
ROCE: 19.7%
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.